222 related articles for article (PubMed ID: 37455550)
21. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.
Liu X; Hao R; Chen S; Guo D; Chen Y
J Gen Virol; 2015 Aug; 96(8):2252-2261. PubMed ID: 25904148
[TBL] [Abstract][Full Text] [Related]
23. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
[TBL] [Abstract][Full Text] [Related]
24. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus.
Ramanan V; Shlomai A; Cox DB; Schwartz RE; Michailidis E; Bhatta A; Scott DA; Zhang F; Rice CM; Bhatia SN
Sci Rep; 2015 Jun; 5():10833. PubMed ID: 26035283
[TBL] [Abstract][Full Text] [Related]
25. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
[TBL] [Abstract][Full Text] [Related]
26. Targeted HBx gene editing by CRISPR/Cas9 system effectively reduces epithelial to mesenchymal transition and HBV replication in hepatoma cells.
Rawal P; Tripathi DM; Hemati H; Kumar J; Tyagi P; Sarin SK; Nain V; Kaur S
Liver Int; 2024 Feb; 44(2):614-624. PubMed ID: 38105495
[TBL] [Abstract][Full Text] [Related]
27. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA.
Seeger C; Sohn JA
Mol Ther; 2016 Aug; 24(7):1258-66. PubMed ID: 27203444
[TBL] [Abstract][Full Text] [Related]
28. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
29. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?
Gao Y; Li Y; Meng Q; Zhang Z; Zhao P; Shang Q; Li Y; Su M; Li T; Liu X; Zhuang H
J Clin Microbiol; 2017 Oct; 55(10):2972-2982. PubMed ID: 28747369
[TBL] [Abstract][Full Text] [Related]
30. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
[TBL] [Abstract][Full Text] [Related]
31. NgAgo-gDNA system efficiently suppresses hepatitis B virus replication through accelerating decay of pregenomic RNA.
Wu Z; Tan S; Xu L; Gao L; Zhu H; Ma C; Liang X
Antiviral Res; 2017 Sep; 145():20-23. PubMed ID: 28709658
[TBL] [Abstract][Full Text] [Related]
32. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus.
Kitamura K; Que L; Shimadu M; Koura M; Ishihara Y; Wakae K; Nakamura T; Watashi K; Wakita T; Muramatsu M
PLoS Pathog; 2018 Jun; 14(6):e1007124. PubMed ID: 29928064
[TBL] [Abstract][Full Text] [Related]
33. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients.
Wang Y; Liu Y; Liao H; Deng Z; Bian D; Ren Y; Yu G; Jiang Y; Bai L; Liu S; Liu M; Zhou L; Chen Y; Chen X; Duan Z; Lu F; Zheng S
Int J Med Sci; 2022; 19(5):858-866. PubMed ID: 35693741
[No Abstract] [Full Text] [Related]
34. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.
Lin SR; Yang HC; Kuo YT; Liu CJ; Yang TY; Sung KC; Lin YY; Wang HY; Wang CC; Shen YC; Wu FY; Kao JH; Chen DS; Chen PJ
Mol Ther Nucleic Acids; 2014 Aug; 3(8):e186. PubMed ID: 25137139
[TBL] [Abstract][Full Text] [Related]
35. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
[TBL] [Abstract][Full Text] [Related]
36. DNA Polymerase κ Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus.
Qi Y; Gao Z; Xu G; Peng B; Liu C; Yan H; Yao Q; Sun G; Liu Y; Tang D; Song Z; He W; Sun Y; Guo JT; Li W
PLoS Pathog; 2016 Oct; 12(10):e1005893. PubMed ID: 27783675
[TBL] [Abstract][Full Text] [Related]
37. Illuminating the Live-Cell Dynamics of Hepatitis B Virus Covalently Closed Circular DNA Using the CRISPR-Tag System.
Ding J; Yi Z; Zai W; Wu M; Chen B; Cai Q; Zhang X; Yuan Z
mBio; 2023 Apr; 14(2):e0355022. PubMed ID: 36840581
[TBL] [Abstract][Full Text] [Related]
38. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Zhu W; Xie K; Xu Y; Wang L; Chen K; Zhang L; Fang J
Virus Res; 2016 Jun; 217():125-32. PubMed ID: 27049051
[TBL] [Abstract][Full Text] [Related]
39. Targeting the hepatitis B cccDNA with a sequence-specific ARCUS nuclease to eliminate hepatitis B virus in vivo.
Gorsuch CL; Nemec P; Yu M; Xu S; Han D; Smith J; Lape J; van Buuren N; Ramirez R; Muench RC; Holdorf MM; Feierbach B; Falls G; Holt J; Shoop W; Sevigny E; Karriker F; Brown RV; Joshi A; Goodwin T; Tam YK; Lin PJC; Semple SC; Leatherbury N; Delaney Iv WE; Jantz D; Rhoden Smith A
Mol Ther; 2022 Sep; 30(9):2909-2922. PubMed ID: 35581938
[TBL] [Abstract][Full Text] [Related]
40. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
